Q2 2026 revenue grew 55% year-over-year to $243.6M, with net income rising to $25.4M. ARCALYST sales guidance for 2026 was raised to $980–$995M, and KPL-387 advanced to Phase 3 trials for recurrent pericarditis.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.